Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A412WV | ISIN: US80880W2052 | Ticker-Symbol:
NASDAQ
24.04.25
21:59 Uhr
4,360 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SCILEX HOLDING COMPANY Chart 1 Jahr
5-Tage-Chart
SCILEX HOLDING COMPANY 5-Tage-Chart

Aktuelle News zur SCILEX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April ...9
MoScilex Holding Co - 8-K, Current Report4
17.04.FDA Grants Scilex Holding Orphan Drug Status For Colchicine To Treat Pericarditis1
16.04.FDA erteilt Orphan-Status für Perikarditis-Medikament von Scilex7
16.04.FDA grants orphan status to Scilex's pericarditis drug1
16.04.Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis87Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Pericarditis is an inflammation of the pericardium...
► Artikel lesen
15.04.Kanada genehmigt Scilex' Migräne-Lösung ELYXYB9
15.04.Canada approves Scilex's migraine solution ELYXYB5
SCILEX Aktie jetzt für 0€ handeln
15.04.Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB's Acute Treatment of ...320ELYXYB® is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1According to market data from 2018, it...
► Artikel lesen
11.04.Scilex Announces 1-for-35 Reverse Stock Split To Regain Nasdaq Compliance10
11.04.Scilex stock rating downgraded at Boral Capital7
11.04.Scilex announces 1-for-35 reverse stock split to meet Nasdaq rules3
11.04.Scilex Holding Company Announces 1-for-35 Reverse Stock Split159PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing...
► Artikel lesen
11.04.Scilex to conduct reverse stock split2
11.04.Scilex Holding Co - 8-K, Current Report3
01.04.Scilex Holding Co - S-8, Securities to be offered to employees in employee benefit plans5
31.03.Scilex Holding Co - 10-K, Annual Report5
27.03.Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva190PALO ALTO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing...
► Artikel lesen
20.03.Scilex Holding Co - 8-K, Current Report6
10.03.Scilex Holding Co - 8-K, Current Report5
Seite:  Weiter >>
75 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1